Targeting TBK1 to overcome resistance to cancer immunotherapy

Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking 1 , 2 . Here we identify the innate immune kinase TANK-binding kinase 1 ( TBK1 ) 3 as a candidate immune-evasion gene in a pooled genetic scre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature (London) 2023-03, Vol.615 (7950), p.158-167
Hauptverfasser: Sun, Yi, Revach, Or-yam, Anderson, Seth, Kessler, Emily A., Wolfe, Clara H., Jenney, Anne, Mills, Caitlin E., Robitschek, Emily J., Davis, Thomas G. R., Kim, Sarah, Fu, Amina, Ma, Xiang, Gwee, Jia, Tiwari, Payal, Du, Peter P., Sindurakar, Princy, Tian, Jun, Mehta, Arnav, Schneider, Alexis M., Yizhak, Keren, Sade-Feldman, Moshe, LaSalle, Thomas, Sharova, Tatyana, Xie, Hongyan, Liu, Shuming, Michaud, William A., Saad-Beretta, Rodrigo, Yates, Kathleen B., Iracheta-Vellve, Arvin, Spetz, Johan K. E., Qin, Xingping, Sarosiek, Kristopher A., Zhang, Gao, Kim, Jong Wook, Su, Mack Y., Cicerchia, Angelina M., Rasmussen, Martin Q., Klempner, Samuel J., Juric, Dejan, Pai, Sara I., Miller, David M., Giobbie-Hurder, Anita, Chen, Jonathan H., Pelka, Karin, Frederick, Dennie T., Stinson, Susanna, Ivanova, Elena, Aref, Amir R., Paweletz, Cloud P., Barbie, David A., Sen, Debattama R., Fisher, David E., Corcoran, Ryan B., Hacohen, Nir, Sorger, Peter K., Flaherty, Keith T., Boland, Genevieve M., Manguso, Robert T., Jenkins, Russell W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking 1 , 2 . Here we identify the innate immune kinase TANK-binding kinase 1 ( TBK1 ) 3 as a candidate immune-evasion gene in a pooled genetic screen 4 . Using a suite of genetic and pharmacological tools across multiple experimental model systems, we confirm a role for TBK1 as an immune-evasion gene. Targeting TBK1 enhances responses to PD-1 blockade by decreasing the cytotoxicity threshold to effector cytokines (TNF and IFNγ). TBK1 inhibition in combination with PD-1 blockade also demonstrated efficacy using patient-derived tumour models, with concordant findings in matched patient-derived organotypic tumour spheroids and matched patient-derived organoids. Tumour cells lacking TBK1 are primed to undergo RIPK- and caspase-dependent cell death in response to TNF and IFNγ in a JAK–STAT-dependent manner. Taken together, our results demonstrate that targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy. Targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy.
ISSN:0028-0836
1476-4687
DOI:10.1038/s41586-023-05704-6